Menstrual disorders. Cefak KG. Active ingredient: extract from chaste tree fruits. since 1948
|
|
- Victoria Lewis
- 5 years ago
- Views:
Transcription
1 Menstrual disorders Active ingredient: extract from chaste tree fruits Cefak KG since
2 Cefak KG Phone +49 (0) 8 31 / Fax +49 (0) 8 31 / Mail Cefak KG. P.O. Box D Kempten/Germany Cefak KG. Ostbahnhofstr. 15. D Kempten/Germany cefak@cefak.com Internet Rev.: 10/2009
3 List of contents page Chaste tree fruits - effective without hormones in case of menstrual disorders, premenstrual syndrome and mastodynia 4 Endocrine gynaecological functional disorders 4 Menstrual irregularities, premenstrual syndrome (PMS), mastodynia 4 Commonness: high prolactin levels 5 Chaste tree fruits a wise therapeutic approach 5 Botany 6 Pharmacology 6 Ingredients determining efficacy 6 Effects 7 Mechanism of action 7 Toxicology 7 Fields of application 8 Clinical efficacy 8 Rational phytotherapy with Vitex agnus castus 8 Contra-indications 10 Tolerability 10 Interaction 10 Kind and duration of application 10 Cefanorm - advantages at a glance 11 Basic information 11 Monograph 13 Literature 15 3
4 Chaste tree fruits - effective without hormones in case of menstrual disorders, premenstrual syndrome and mastodynia Today, Chaste tree (monk s pepper, Vitex agnus castus) plays an important role in gynaecology as a therapy with hormone preparations often is not reasonable due to the high potential of side effects and should therefore not be used at all for certain diseases. The fruits of the Chaste tree (Agni casti fructus) are used successfully for the treatment of menstrual disorders, premenstrual syndrome and mastodynia. A therapy with Chaste tree often alleviates the complaints clearly or even eliminates them. In addition to somatic complaints (feelings of swelling and tension in the breasts, headache, edema, abdominal bloating, constipation), also the psychic impairments (irritability, depressive moods, nervousness) are improved demonstrably. In the longterm, this results in a stabilisation of the female hormonal regulative circle. Endocrine gynaecological functional disorders Menstrual irregularities, premenstrual syndrome (PMS), mastodynia Menstrual irregularities can be characterised as absence (secondary amenorrhea) as well as too rarely (oligomenorrhea) or too frequently (polymenorrhea) occurring of menstrual outflows. A hyperprolactinemia can often be verified whereas the level of prolactin correlates with the severity of the cycle disorders. By means of a reduction of the prolactin level, normal cycle functions mostly can be restored. The premenstrual syndrome is a complex of complaints consisting of somatic (headache, painful swelling resp. hyperaesthesia of the breasts, breast tension, edema) and psychic complaints (psychic states of tension, nervousness, restlessness, anxiety, decrease in vitality, lack of concentration, emotional changes, depressions) which start before menstruation and disappear with menstruation. The etiology is largely unexplained. Increased estrogen/progesterone-quotients, hyperprolactinemia and excessive neurotransmitter effects as a result of hormonal change-over at the end of the cycle are discussed among others. 4
5 Mastodynia can mostly be described as painful tension and swelling of the mammary gland, which in general increases in the second half of the cycle and decreases after onset of the period. Secretory anomalies of prolactin have to be considered as releasing factor. mamilla Commonness: high prolactin levels lactiferous gland (mammary gland) Premenstrual syndrome, cycle disorders, infertility. All these complaints and clinical pictures have something in common: They are associated to high prolactin levels. Thus, menstrual and fertility disorders are closely related with an excessive secretion of prolactin from the lactogenic cells of the hypophysis. Hyperprolactinemia is one of the most frequent reasons for a corpus luteum insufficiency. The premenstrual syndrome with its direct symptom of mastodynia is attributed to a latent hypersecretion of prolactin. That means that due to a stimulus, the lactogenic cells of the hypophysis temporarily release unphysiologic amounts of prolactin. Thereby, the mammary gland is stimulated chronically and reacts with typical mastodynia symptoms such as pain and feeling of tension. Chaste tree fruits a wise therapeutic approach A wise therapeutic approach is now to restrict the excessive release of prolactin, possible by influencing the dopaminergic system. The neurotransmitter dopamine acts as natural inhibitor of the release of prolactin from the adenohypophysis. But this approach has not proved its worth as dopamine is instable and is quickly transferred into its inactive form in the organism. Interestingly, preparations from Chaste tree contain dopaminagonists. Investigations have shown that certain ingredients of the extract (probably bi-cyclic diterpenes) bind to the dopamine receptor from type 2 of the lactogenic hypophyseal cells. That way, the release of prolactin can be restricted. A simple but effective mechanism of action! 5
6 Botany Chaste tree Chaste tree is a shrub up to 4 m high. The leaves are crossed-opposite, long-stemmed and separated finger-shaped with up to 7 lanceolate feathered small leaves. The mauve, ear-like inflorescences build reddish-black, peppercorn-sized drupes. Time of prosperity: June to September Vitex agnus castus L. Family: Verbenaceae (vervain plants) Synonyms: Origin: Monk s pepper, Mönchspfeffer, Keuschlamm, Abrahamstrauch Mediterranean area, Central Asia, Isle Krim. Preferably also on brooksides and riversides. Medicinal drug: Chaste tree fruits (Agni casti fructus), consisting of the ripe, dried fruits. Pharmacology A positive monograph of the BfArM (Federal Institute for Drugs and Medical Devices), Commission E, exists for the active ingredient Chaste tree fruits. Ingredients determining efficacy iridoid glycosides (aucubin, agnoside) lipophile flavonoids essential oil fatty oil 6
7 Effects inhibition of the prolactin secretion and thus, reduction of increased prolactin levels dopaminergic effect (central nervous component by influence on the catecholamine excretion) balancing on the prolactin level (inhibition of prolactin secretion of the hypophysis in case of too high prolactin level, increase in case of too low level) inhibition of lactation (experiments in animals) Mechanism of action For Vitex agnus castus a prolactin-inhibiting effect as a result of a dopaminergic effect was shown by cell-biological and animal experimental investigations. The effect aims at the hypophyseal portal system. Dopaminergic principle of effect: Selective stimulation of dopamine-2-receptors at the hypophyseal, so-called lactogenic cells. Thereby, the effect of the Chaste tree fruits is dependent on dose and initial situation, i.e. in case of low prolactin level, the secretion is increased, in case of high values, the release is inhibited. The most recent results of the pharmacological profile of an extract from Vitex agnus castus show an outstanding affinity to the dopamine-d3-receptor which is mainly located in the mesolimbic system. On the human estrogen-a-receptor no affinity was observed which is important from the safety point of view. Therefore, there is no direct danger for the proliferation of breast cancer cells. Toxicology Systematic investigations with regard to toxicology do not exist. 7
8 Fields of application Traditional Chaste tree was already used in the antique for women s diseases, especially for fertility disorders. The present common Latin name Agnus castus is derived from the Latin castus (chaste) and the equalisation with agnus (lamb). According to the Greek mythology, the goddess Hera - adored as guardian of the marriage - was born below an Agnus castus shrub. Even nowadays the branches of Vitex agnus castus are considered to be a symbol for chastity. Thus, the German names Keuschlamm and Mönchspfeffer can be explained. Gynaecology For all symptoms of corpus luteum insufficiency and estrogen-progesterone-imbalance. Clinical efficacy Rational phytotherapy with Vitex agnus castus Menstrual irregularities Roeder realised a controlled study against placebo in which the efficacy for elimination of menstrual irregularities is verified clearly. It was also shown that increased prolactin levels, existing before start of the therapy, could be reduced during the treatment (12). The effect can also be understood from the pharmacological point of view as menstrual disorders are frequently related to a corpus luteum insufficiency. Thus, the luteinizing effect of a preparation from Chaste tree fruits has a positive influence on the events. Premenstrual syndrome The premenstrual syndrome is based on a hormonal imbalance whereas finally it is not clarified if a too high estrogen level or a too low gestagen level is responsible. Again, the luteinizing effect is reasonable from the therapeutic point of view in order to restore the disordered balance and to improve the symptoms. 8 By means of an Agnus castus extract it is possible to alleviate the premenstrual complaints of the affected women efficiently, mostly the effect can be noted after 1 to 2 months. In the meantime, these results have been confirmed by open clinical mono resp. multicentre long-term studies (2, 7). The most frequent and most
9 important symptoms such as headache, breast tension, peripheral edema, psychic states of tension, nervousness, restlessness, anxiety, aggressions, decrease in vitality, lack of concentration, emotional changes and depressions showed a clear improvement. Double-blind study: The treatment of PMS with monk s pepper is effective A placebo-controlled, randomised double-blind study investigated the influence of monk s pepper for PMS. 87 women received one tablet Agnus castus daily and 91 women received placebo over a period of 3 menstrual cycles. 90 % of all women finished the study. From the statistical point of view, Agnus castus proved to be significantly more effective than placebo in the treatment of premenstrual complaints. The symptoms improved in 52 % of the women in the verum group. In the investigated variables irritability, mood swings, aggressiveness, headache, breast tensions and other premenstrual syndromes, a significant reduction to placebo could be shown (13). Mastodynia In general, mastodynia can not be described as an independent clinical picture but rather as a symptom within the scope of the premenstrual syndrome. Likewise, a positive influence can be noted. The active ingredients of the extract have an impact on the release of the neurotransmitter dopamine and thus, normalise the release of prolactin in the hypophysis. That way, the inconvenient feeling of tension and swelling in the breast before menstruation is reduced. These results could be confirmed in a double-blind, randomised comparative clinical trial with female patients suffering from cyclically recurrent mastodynia (5). Two double-blind studies according to GCP-guidelines Two further randomised, placebo-controlled double-blind studies were carried out in female patients with painful mastodynia over 3 cycles according to the GCP-guidelines (Good Clinical Practise). For the evaluation of the efficacy, the intensity of the breast pains had to be marked on a visual pain scale. At the end of the study, the difference between verum and placebo was significant. Verum did not have any influence on progesterone, FSH (follicle-stimulating hormone) and LH (luteinizing hormone). The 17β-estradiol-values dropped more strongly under verum than under placebo. After verum, the basal prolactin values were significantly below the placebo values (8). Fertility disorders In a randomised double-blind study, 37 women suffering from fertility disoders because of latent hyperprolactinemia were treated over 3 months. In the group of women treated with verum, the release of prolactin after stimulation decreased significantly. The duration of the menstrual cycles remained the same in both groups. Whereas the duration of the luteal phases remained constant in the placebo group, 9
10 it increased clearly from 5.5 to 10.5 days under therapy with Agnus castus. Mid-luteally suppressed progesterone- and 17β-estradiol levels increased under the extract. After the end of the treatment, only 2 of 9 women complained about premenstrual disorders, 2 women of the verum group became pregnant (11). As shown by further investigations, it is worth to use Chaste tree in case of an unfulfilled desire for children. Preparations from Chaste tree fruits normalise the functions of corpus luteum. Therefore, the extract can help in cases where the infertility is attributed to disorders in the production of corpus luteum. Contra-indications Preparations from Chaste tree fruits should not be taken in when suffering from hypersensitivity to Chaste tree. So far it is not known if Agnus castus could influence tumours of the hypophysis or the mammary gland. Therefore, patients suffering from hypophyseal tumours and mamma carcinoma should be excluded from the therapy. Based on the mechanism of action, a use in pregnancy seems not to be reasonable and should not be taken into consideration with regard to the indication either. Experiments in animals show an impairment of milk production. Tolerability Rarely there can be itching, urticarial skin changes. In case of allergic reactions, the intake of the medicament has to be stopped. Interaction Due to the postulated dopaminergic effect, an alternating weakening of the effect is possible in case of administration of dopamine-receptor-antagonists. Kind and duration of application Preparations from Chaste tree fruits should always be taken in at the same time of day and at least over 3 menstrual cycles. 1 capsule daily resp drops once daily. This corresponds to the effective daily dose stipulated in the monograph. Risks from an intake on a long-term basis are not apparent. 10
11 Cefanorm - advantages at a glance normalises cycle disorders in a natural and gentle way stimulates corpus luteum reduces prolactin level does not contain any hormones Basic information Fields of application: irregularities of the menstrual cycle, sensations of tension and swelling in the breasts (mastodynia), monthly recurring complaints before the onset of the menstruation (premenstrual symptoms). In the leaflet the following is pointed out to the patient: in case of feelings of tension and swelling in the breasts as well as disorders in menstruation, a physician should be consulted since there may be underlying diseases for which a medical examination may be essential. Composition: Active ingredient: Hard capsules: 1 hard capsule contains: dry extract from chaste tree fruits (7-13 : 1) 4 mg. Extraction solvent: ethanol 60% (m/m). Drops: 100 g (= 109 ml) contain: (1 ml corresponds to 40 drops) tincture from chaste tree fruits (1:5) 20 g. Extraction solvent: ethanol 70% v/v. Excipients: Hard capsules: glucose syrup, lactose monohydrate, talc, maize starch, magnesium stearate, colloidal anhydrous silica, gelatin, sodium laurilsulfate (dodecylsulfate), purified water, dyestuff E171. Drops: ethanol 96%, purified water. Contra-indications: Cefanorm must not be used in case of - hypersensitivity to chaste tree fruits (monk s pepper) or to one of the excipients of the pharmaceutical - hypophyseal tumour - mammary carcinoma. Application during pregnancy and lactation: due to not sufficient investigations and because of the alcohol content of the drops, Cefanorm 11
12 must not be taken in during pregnancy and lactation. After administration of chaste tree fruits (monk s pepper) an impairment of milk production was observed in animal experiments. Additionally for drops: do not apply in case of alcohol disease. Due to the alcohol content, Cefanorm drops should only be taken in by liver patients, epileptics, brain patients or braindamaged patients after consultation of a physician. Interactions with other substances: interactions are not known. There are references - based on experiments in animals - to a dopaminergic effect of the drug; thus an alternating weakening of the effect could be possible in case of administration of dopamine-receptor-antagonists. Warning: Hard capsules: patients suffering from the rare hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption, should not take Cefanorm. Drops: Cefanorm drops contain 55 vol.-% alcohol. Dosage: Hard capsules: intake of 1 hard capsule daily (corresponding to 40 mg drug). Drops: unless otherwise prescribed, adults take in drops in the morning before eating and drinking. Kind and duration of application: Hard capsules: Cefanorm hard capsules should preferably always be taken in at the same time of day. Drops: Cefanorm drops are taken in diluted with some liquid (e.g. water). The preparation should be taken in over 3 menstrual cycles at least. Undesirable effects: Hard capsules: occasionally headache, itching, abdominal complaints such as nausea, stomach ache or pains in the lower abdomen as well as systemic hypersensitivity reactions with exanthema, urticaria, facial swelling, dyspnea and swallowing complaints. Drops: after intake of pharmaceuticals containing chaste tree fruits, headache, itching, abdominal complaints such as nausea, stomach ache or pains in the lower abdomen are described. Cases of systemic hypersensitivity reactions with exanthema, urticaria, Quinke edema, dyspnea and swallowing complaints are described as well. In the leaflet, the patient is instructed to stop the intake and immediately consult a physician in case of signs of hypersensitivity reactions. In the leaflet, the following is pointed out to the patient: in case of occurrence of above mentioned undesirable effects, stop the intake of the preparation and consult a physician. If you notice undesirable effects, not mentioned in this leaflet, inform your physician or pharmacist. Commercial forms: Hard capsules: 30 pcs., 60 pcs., 100 pcs. Drops: 100 ml 12
13 Monograph Chaste Tree fruit, Agni casti fructus Official Monograph of the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (German Federal Institute for Drugs and Medical Devices) Commission E (Phytotherapy), BAnz.-No. 226 dated December 02, 1992 Name of Drug Agni castus fructus; chaste tree fruit, vitex fruit. Composition of Drug Chaste tree fruit composed of the ripe, dried fruits of Vitex agnus castus L. [Fam. Verbenaceae], as well as their preparations in effective dosage. Pharmacological Properties, Pharmacokinetics, Toxicology There is evidence that aqueous-alcoholic extracts of chaste tree fruit inhibit secretion of prolactin in vitro. In human pharmacology there are no data about the lowering of prolactin levels. There is no knowledge regarding pharmacokinetics. Systematic studies about toxicology are unknown. Clinical data 1. Uses Irregularities of the menstrual cycle. Premenstrual complaints. Mastodynia. Note: In case of feeling of tension and swelling of the breasts and at disturbances of menstruation, a physician should be consulted for diagnosis. 2. Contraindications None known. 3. Undesirable Effects Occasional occurrence of itching, urticarial exanthemas. 4. Special Cautions for Use None known. 5. Use During Pregnancy and Lactation No application during pregnancy. In animal experiments an influence on the nursing performance was observed. 6. Interactions with Other Drugs Interactions are unknown. In animal experiments there is evidence of a dopaminergic effect of the drug; therefore, a reciprocal weakening of the effect can occur in case of ingestion of dopamine-receptor antagonists. 13
14 7. Dosage Unless otherwise prescribed: Daily dosage: aqueous-alcoholic extracts corresponding to mg of the drug. 8. Mode of Administration Aqueous-alcoholic extracts (50 70 percent v/v) from the crushed fruits taken as liquid or dry extract. 9. Overdosage None known. 10. Special warnings None known. 11. Effects on Operators of Vehicles and Machines None known. 14
15 Literature 1 Chaste Tree fruit, Agni casti fructus: Official Monograph of the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (German Federal Institute for Drugs and Medical Devices) Commission E (Phytotherapy), BAnz.-No. 226 dated December 02, Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A, (2000): Efficacy of Vitex agnus castus L. extract Ze 440 in patients with premenstrual syndrome (PMS). Arch Gynecol Obstet. Nov; 264 (3): ESCOP-Monographs, (2003): Herbal Medicinal Products, G. Thieme Verlag, Stuttgart 4 Hänsel, et al. (Hrgs.), (1994): Vitex. Auszug aus Hagers Handbuch der pharmazeutischen Praxis, Band 6, Drogen P - Z.: Springer-Verlag, Halaska M, Beles P, Gorkow C, Sieder C, (1999): Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast. 8 (4): Houghton P, (1994): 4. Agnus Castus. The Pharmaceutical Journal (Vol. 253), Loch EG, Selle H, Boblitz N, (2000): Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med. 9 (3): Loew D, Habs M, Klimm HD, Trunzler G, (1999): Phyto-Pharmaka Report. Rationale Therapie mit pflanzlichen Arzneimitteln. Steinkopff, Darmstadt 9 Meier B, Berger D, Hoberg E, Sticher O, Schaffner, (2000): Pharmacological activities of Vitex agnuscastus extracts in vitro. Phytomedicine 7 (5): Meier B, Hoberg E, (1999): Agni-casti fructus. Neue Erkenntnisse zur Qualität und Wirksamkeit. Zeitschrift für Phytotherapie 20: Milewicz A, Gejdel E, Sworen H, Sienkiewicz K, Jedrzejak J, Teucher T, Schmitz H, (1993): [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study] Arzneimittelforschung 43 (7): Roeder D, (1994): Therapie von Zyklusstörungen Vitex agnus-castus. Zeitschrift für Phytotherapie 15, Schellenberg R, et al., (2001): Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 322: Schilcher H, Kammerer S, (2003): Leitfaden Phytotherapie. 2. Auflage Urban & Fischer 15 Weiß RF, (1991): Vitex agnus castus. Auszug aus dem Lehrbuch der Phytotherapie. Hippokrates Verlag Stuttgart, 7. Auflage, Wenigmann M, (1999): Phytotherapie. Arzneipflanzen Wirkstoffe Anwendung. Urban & Fischer 17 Wuttke W, Gorkow C, Jarry H; (1995): Dopaminergic compounds in Vitex Agnus Castus. In: Phytopharmaka in Forschung und klinischer Anwendung von Loew D, Rietbrock N (Hrsg.), Steinkopff, Darmstadt, Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D, (2003): Chaste tree (Vitex agnuscastus)-pharmacology and clinical indications. Phytomedicine May; 10 (4): Van Wyk BE, Wink C, u. Wink M, (2004): Handbuch der Arzneipflanzen, Wiss. Verlagsges.mbH, Stuttgart 15
16 Rev.: 10/2009 since 1948 P.O. Box D Kempten/Germany Cefak KG
Chasteberry Snapshot Monograph
herbs Chasteberry Snapshot Monograph Chasteberry (Vitex agnuscastus) Most Frequent Reported Uses: - Helps balance pituitary function. - Helps balance sex hormonal levels for men and women. - Reported progesterone
More informationChaste tree, Chasteberry, Monk s pepper
Vi t e x a g n u s - c a s t u s Chaste tree, Chasteberry, Monk s pepper Pa rt Us e d The ripe, dried fruit C o m m o n / Pote n t i a l Us e s Premenstrual syndrome (PMS) Breast tenderness/pain associated
More informationCan Vitex Agnus Castus be Used for the Treatment of Mastalgia? What is the Current Evidence?
Advance Access Publication 17 November 2007 ecam 2008;5(3)247 250 doi:10.1093/ecam/nem074 Review Can Vitex Agnus Castus be Used for the Treatment of Mastalgia? What is the Current Evidence? A. R. Carmichael
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VITEX AGNUS-CASTUS L., FRUCTUS
European Medicines Agency Evaluation of Medicines for Human Use London, 17 September 2009 Doc. Ref.: EMEA/HMPC/144006/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH
More informationMetoclopramide hydrochloride mg (Quantity corresponding to anhydrous metoclopramide hydrochloride) mg
Name Primperan 10 mg Breakable tablets Metoclopramide hydrochloride Before taking this medicine Carefully read the entirety of this leaflet before taking this medicine. It contains important information
More informationEuropean Union herbal monograph on Vitex agnus-castus L., fructus
27 March 2018 EMA/HMPC/606742/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Vitex agnus-castus L., fructus Final Initial assessment Discussion in Working Party on
More informationCommunity herbal monograph on Vitex agnus-castus L., fructus
25 November 2010 EMA/HMPC/144006/2009 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Vitex agnus-castus L., fructus Final Discussion in Working Party on Community monographs
More informationAt the completion of this monograph, you will be able to:
1 Vitex agnus-castus Performance Objectives At the completion of this monograph, you will be able to: Chaste Tree Taxonomic Notes Name the botanical and family name of chaste tree, Vitex agnus-castus.
More informationPublic Assessment Report for a Traditional Herbal Medicinal Product for Human Use
IPAR Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use Agnus castus oral drops Tincture of Agnus castus fruit TR2309/017/001 A. Vogel Ireland Limited 28 November 2018 CRN008R68
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Atrosan Devil's Claw film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 480 mg of extract
More informationEmergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains
More informationUser information: Please read carefully! Cough syrup
User information: Please read carefully! Cough syrup Active ingredient: Marshmallow root extract Herbal medicinal product Content of user information: Indication group and areas of application Contraindications
More informationRemifemin plus Coated tablets, dry extract of St. John s Wort and Cimicifuga rhizome
Package leaflet: information for the user Remifemin plus Coated tablets, dry extract of St. John s Wort and Cimicifuga rhizome Read all of this leaflet carefully because it contains important information
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:
Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is
More informationPATIENT INFORMATION LEAFLET TEXAMER
SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,
More informationVALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics
Sandoz Business use only Page 1 of 5 Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Valeriaan Sandoz omhulde tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains
More informationNew Zealand Datasheet
New Zealand Datasheet 1 PRODUCT NAME POSTINOR-1 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Levonorgestrel 1.5 mg 3 PHARMACEUTICAL FORM Each round white tablet contains 1.5 mg of levonorgestrel. The tablet
More informationPATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE
SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each
More informationAvailable online at Journal of Agroalimentary Processes and Technologies 2012, 18 (2),
Available online at http://journal-of-agroalimentary.ro Journal of Agroalimentary Processes and Technologies 212, 18 (2), 12-126 Journal of Agroalimentary Processes and Technologies Process management
More informationHedelix Cough Effervescent Tablets are used to relieve symptoms of chronic inflammatory bronchial conditions; for colds affecting the airways.
Package leaflet: Information for the patient Hedelix Cough Effervescent Tablets 50 mg Active substance: ivy leaf dry extract Read all of this leaflet carefully before you start taking this medicine because
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationTherapeutic Effect of Vitex Agnus Castus in Patients with Premenstrual Syndrome
ORIGINAL REPORT Therapeutic Effect of Vitex Agnus Castus in Patients with Premenstrual Syndrome Mehrangiz Zamani 1, Nosrat Neghab 1, and Saadat Torabian 1 Department of Obstetrics & Gynecology, Hamedan
More information1. What Betahistine dihydrochloride tablets is and what it is used for
Package leaflet: Information for the user Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets Betahistine dihydrochloride Read all of this leaflet carefully before you start
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationURSOSAN 250mg capsule, hard
PACKAGE LEAFLET: INFORMATION FOR THE USER URSOSAN 250mg capsule, hard URSODEOXYCHOLIC ACID This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More information3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mebeverine hydrochloride 135 mg coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 135 mg of mebeverine
More informationPackage leaflet: Information for the user. Ebateva 20 mg Orodispersible Tablets. Ebastine
Package leaflet: Information for the user Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets Ebastine Read all of this leaflet carefully before you start taking this medicine because
More informationCHASTE TREE. Vitex agnus-castus L. (Lamiaceae) (McGuffin et al. 2000; USDA 1998) Source material(s): Fruit/Berry (Blumenthal 2000; Mills & Bone 2000)
CHASTE TREE This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended
More informationOverview of comments received on Community herbal monograph on Leonurus cardiaca L., herba (EMA/HMPC/561942/2010)
16 September 2010 EMA/HMPC/561942/2010 Committee on Herbal Medicinal Products (HMPC) Overview of comments received on Community herbal monograph on Leonurus cardiaca L., herba (EMA/HMPC/561942/2010) Table
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Mebeverine Tablets BP 135 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 135 mg of Mebeverine Hydrochloride
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationPackage leaflet for emergency supplies
Version: August 2014 No.: 57204.00.00 Package leaflet for emergency supplies This is a special medicine to be taken in the event of radiation accidents involving the release of radioactive iodine. It must
More informationSibelium 5 mg Tablets flunarizine
J-C 2017 Sibelium 5 mg Tablets flunarizine PACKAGE LEAFLET: INFORMATION FOR THE USER Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationPyrazinamide 500 mg Tablets (Macleods Pharmaceuticals Ltd), TB243. WHOPAR part 3 April 2014 Section 6 updated: May 2014 PACKAGE LEAFLET.
PACKAGE LEAFLET Page 1 of 6 PACKAGE LEAFLET: INFORMATION FOR THE USER Pyrazinamide 500 mg Tablets * Pyrazinamide Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationYour Monthly Update. Mastalgia. Did you know: Dear Colleague. Welcome to the January 2013 newsletter from Pure Bio Ltd.
Your Monthly Update Dear Colleague Welcome to the January 2013 newsletter from Pure Bio Ltd. Did you know: A high carbohydrate diet is a direct cause of mild dementia and memory loss in ageing. Those who
More informationPATIENT INFORMATION LEAFLET POLLENTYME S AND TABS
SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS (tablets) POLLENTYME S (syrup) Read all of this leaflet carefully because it contains important information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betahistine dihydrochloride 8 mg tablets Betahistine dihydrochloride 16 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betahistine
More informationDialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride
PACKAGE LEAFLET: INFORMATION FOR THE USER Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may
More informationAtrosan Devil s Claw film-coated tablets
: INFORMATION FOR THE USER Atrosan Devil s Claw film-coated tablets Read all of this leaflet carefully before you start taking this product because it contains important information for you. Always take
More informationPackage leaflet: Information for the patient. Torarese 2.5 mg tablets Torarese 5 mg tablets Torarese 10 mg tablets Torarese 20 mg tablets.
Package leaflet: Information for the patient Torarese 2.5 mg tablets Torarese 5 mg tablets Torarese 10 mg tablets Torarese 20 mg tablets Torasemide Read all of this leaflet carefully before you start taking
More informationRead all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Package leaflet: Information for the patient Hedelix Effervescent Tablets Active substance: ivy leaf dry extract Read all of this leaflet carefully before you start taking this medicine because it contains
More informationConsumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules.
Clindamycin hydrochloride Capsules 150 mg What is in this leaflet Consumer Medicine Information TOPICIL Please read this leaflet carefully before you start using Topicil Capsules. This leaflet answers
More informationPackage leaflet: Information for the user. Flutamid Stada 250 mg tablets Flutamide
Package leaflet: Information for the user Flutamid Stada 250 mg tablets Flutamide Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More informationPackage leaflet: Information for the user. Melatonin Pharma Nord 3 mg, film-coated tablets melatonin
Package leaflet: Information for the user Melatonin Pharma Nord 3 mg, film-coated tablets Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationMODUS TABLETS. Medroxyprogesterone Tablets IP
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory MODUS TABLETS Medroxyprogesterone Tablets IP QUALITATIVE AND QUANTITATIVE COMPOSITION MODUS TABLET 2.5 mg Each uncoated
More informationOrgalutran 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 1. NAME OF THE MEDICINAL PRODUCT 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 0.25 mg of ganirelix (INN) in 0.5 mg aqueous solution.
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ORILISSA. elagolix (as elagolix sodium) tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ORILISSA elagolix (as elagolix sodium) tablets Read this carefully before you start taking ORILISSA and each time you
More informationMEDICATION GUIDE LAMOTRIGINE TABLETS
MEDICATION GUIDE LAMOTRIGINE TABLETS (Chewable, Dispersible) Read this Medication Guide before you start taking lamotrigine and each time you get a refill. There may be new information. This information
More informationEpilepsy is a condition where you have repeated seizures (fits). There are many different types of seizures, ranging from mild to severe.
CONSUMER MEDICINE INFORMATION Levetiracetam generichealth Levetiracetam tablets What is in this leaflet Please read this leaflet carefully before you take this medicine. This leaflet answers some common
More informationPATIENT INFORMATION LEAFLET DYNARB RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNARB 75 mg tablets DYNARB 150 mg tablets DYNARB 300 mg tablets Read all of this leaflet carefully before you start taking DYNARB.
More information2. What you need to know before you take DDAVP/Desmopressin Tablets
Package Leaflet: Information for the user DDAVP /Desmopressin 0.1mg Tablets Desmopressin Acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationVitex agnus-castus Extracts for Female Reproductive Disorders: A Systematic Review of Clinical Trials
562 Reviews Vitex agnus-castus Extracts for Female Reproductive Disorders: A Systematic Review of Clinical Trials Authors M. Diana van Die 1, Henry G. Burger 2, Helena J. Teede 3, Kerry M. Bone 4 Affiliations
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Dimaval 250 mg DMPS-Na/5 ml Solution for injection Active substance:(rs)-2,3-bis(sulfanyl)propane-1-sulfonic acid, sodium-salt 1 H 2 O Read all of this leaflet
More informationPage 1 of 5 VERZENIO abemaciclib tablet Eli Lilly and Company AddendaIndex Summary View All Sections HIGHLIGHTS OF PRESCRIBING INFORMATION FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE
More informationPackage leaflet: Information for the user. CYPROSTAT 50 mg tablet cyproterone acetate
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end
More informationAssessment report on Vitex agnus-castus L., fructus
27 March 2018 EMA/HMPC/606741/2018 Committee on Herbal Medicinal Products (HMPC) Final Based on Article 10a of Directive 2001/83/EC (well-established use) Based on Article 16d(1), Article 16f and Article
More informationSIBELIUM Capsules Janssen
SIBELIUM Capsules Janssen NAME OF THE MEDICINAL PRODUCT Trade name SIBELIUM International Non-Proprietary Name (Modified) (rinnm) flunarizine hydrochloride QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Histabentine 8 mg/16 mg tablets. Betahistine dihydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE USER Histabentine 8 mg/16 mg tablets Betahistine dihydrochloride Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL
European Medicines Agency Evaluation of Medicines for Human Use London, 6 November 2008 Doc. Ref.: EMEA/HMPC/251323/2006 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON
More informationHypoglycemia. When recognized early, hypoglycemia can be treated successfully.
Hypoglycemia Introduction Hypoglycemia is a condition that causes blood sugar level to drop dangerously low. It mostly shows up in diabetic patients who take insulin. When recognized early, hypoglycemia
More informationOtezla (apremilast) film coated tablets
New Zealand Consumer Medicine Information Otezla (apremilast) film coated tablets WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Otezla. It does not contain all the available
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. AZITHROMYCIN Azithromycin Tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr AZITHROMYCIN Azithromycin Tablets Read this carefully before you start taking AZITHROMYCIN and each time you get
More informationPATIENT INFORMATION LEAFLET. Testosterone Enantate 250mg/ ml Solution for Injection Testosterone Enantate
PATIENT INFORMATION LEAFLET Testosterone Enantate 250mg/ ml Solution for Injection Testosterone Enantate Read all of this leaflet carefully before you start using this medicine because it contains important
More informationPackage leaflet: Information for the patient. Megalac Almasilate 1 g/10 ml suspension. Active substance: almasilate
Package leaflet: Information for the patient Megalac Almasilate 1 g/10 ml suspension Active substance: almasilate Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate
PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read
More informationEndocrine Glands. Endocrine glands
ENDOCRINOLOGY Endocrine Glands Endocrine glands Produce substances called hormones. Ductless glands, i.e., they release hormones directly into the bloodstream Hormones only act at their target tissue where
More informationDulcolax 5 mg, film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Dulcolax 5 mg, film-coated tablets BISACODYL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Irbesartan 75mg Film-coated Tablets Irbesartan 150mg Film-coated Tablets Irbesartan 300mg Film-coated Tablets irbesartan Read all of this leaflet carefully before
More informationPackage leaflet: Information for the user. Tetrabenazine 25 mg tablets. tetrabenazine
Package leaflet: Information for the user Tetrabenazine 25 mg tablets tetrabenazine Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationVitex Berry Essential Oil
Vitex Berry Essential Oil Family: Lamiaceae (also placed in Verbenaceae) Common names: Chaste Tree, Chasteberry, Monks Pepper Botanical name: Vitex agnus-castus L. Plant part used: Berries. An essential
More informationNeuro-Medivitan is a vitamin preparation. Intended use Systemic neurological disorders due to proven deficiency of vitamins B1 and B6.
Unofficial translation of the German package leaflet Patient Information Leaflet: Information for users Neuro-Medivitan, film-coated tablets Active substances: thiamine chloride hydrochloride / pyridoxine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,
More informationCore Safety Profile. Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% SK/H/PSUR/0005/001 Date of FAR:
Core Safety Profile Active substance: Terbinafine Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% P-RMS: SK/H/PSUR/0005/001 Date of FAR: 08.06.2012 4.3 Contraindications Hypersensitivity
More informationRead all of this leaflet carefully before you start taking this medicine.
Package Leaflet: Information for the User Tamoxifen 10mg Tablets Tamoxifen Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If
More informationPATIENT INFORMATION LEAFLET BILOCOR RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM BILOCOR 5 tablets BILOCOR 10 tablets Please read this leaflet carefully before using BILOCOR 5 / 10 mg tablets Keep this leaflet.
More informationNORPROLAC (quinagolide)
NORPROLAC (quinagolide) COMPOSITION Tablets containing 25, 50, 75 or 150 micrograms (0.025, 0.050, 0.075 or 0.150 mg) quinagolide as the hydrochloride. Norprolac Tablets also contain the following inactive
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Cyproteronacetate 50 PCH 50 mg tablets Cyproteronacetate
PACKAGE LEAFLET: INFORMATION FOR THE USER Cyproteronacetate 50 PCH 50 mg tablets Cyproteronacetate Page: 1 Read all of this leaflet carefully before you start taking this medicine Keep this leaflet. You
More informationXYZAL 5 MG FILM-COATED TABLET
XYZAL 5 MG FILM-COATED TABLET Levocetirizine dihydrochloride Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However,
More informationPATIENT INFORMATION LEAFLET FOR FEDALOC 30 mg / 60 mg SR TABLETS. Please read this leaflet carefully before you start taking FEDALOC tablets.
1 Module 1.5.5.2 Patient information leaflet PATIENT INFORMATION LEAFLET FOR FEDALOC 30 mg / 60 mg SR TABLETS Please read this leaflet carefully before you start taking FEDALOC tablets. Keep this leaflet.
More informationART 50 Capsules. Symptomatic treatment of functional symptoms and signs of osteoarthritis.
Doctor leaflet Art50-DL-March2012-01 ART 50 Capsules 1. NAME OF THE MEDICINAL PRODUCT Art 50 mg, capsule. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule of ART 50 contains Diacerein 50 mg. For
More informationPOLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS
PROPOSED FINAL PATIENT INFORMATION LEAFLET FOR POLLENTYME TABLETS & POLLENTYME S PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PALLIDA (NUTT.) NUTT., RADIX
European Medicines Agency Evaluation of Medicines for Human Use London, 16 July 2009 Doc. Ref.: EMEA/HMPC/332350/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium
PACKAGE LEAFLET: INFORMATION FOR THE USER Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium Read all of this leaflet carefully before you start taking this medicine because it contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationDomperidon Betapharm 10 mg tablets. Summary of Product Characteristics. 1:(to be changed into local product name in each CMS after day 90)
1. NAME OF THE MEDICINAL PRODUCT Domperidone Betapharm10 mg, tablets 1 Summary of Product Characteristics 1:(to be changed into local product name in each CMS after day 90) 2. QUALITATIVE AND QUANTITATIVE
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Irbea 75 mg film-coated tablets Irbesartan
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbea 75 mg film-coated tablets Irbesartan Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationPATIENT INFORMATION LEAFLET
FERIFER-40 Oral Solution, 40 mg/5 ml For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each one spoon solution (5 ml) contains 40 mg of iron (as iron III polymaltose complex). Excipient(s):
More informationAgreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder
CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...
More information2006 CE Series Lesson Two An Overview of The Premenstrual Syndrome ACPE Universal Program No H01 Expiration Date: 1/31/09
2006 CE Series Lesson Two An Overview of The Premenstrual Syndrome ACPE Universal Program No. 406-000-06-002-H01 Expiration Date: 1/31/09 by H. David Bergman, Ph.D. Dean, Southwestern Oklahoma State University,
More information100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L., folium) ( 4-8:1). Extraction solvent: ethanol 30% (m/m).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hedussin syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 100 ml of the syrup contain 825 mg of ivy leaf dry extract (Hedera helix L.,
More informationCOMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AESCULUS HIPPOCASTANUM L., SEMEN
European Medicines Agency Evaluation of Medicines for Human Use London, 16 July 2009 Doc. Ref.: EMEA/HMPC/225319/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AESCULUS
More informationMELATONIN Insomnia and Sleep Disorders in Children
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which
More information